Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22599583 | 0.98 | CYP2A6 (0.54) | CYP2A6CYP1A2TDP1CA9CA12 | |
| SCHEMBL169650 | 0.79 | MAOA (0.54) | TDP1CA9PIM1KDM4EAPAF1 | |
| SCHEMBL22599584 | 0.77 | CYP2A6 (0.64) | CYP2A6CYP1A2TDP1CA9CA12 | |
| SCHEMBL6888140 | 0.75 | CYP1A2 (0.87) | CYP2A6CYP1A2TDP1CA9CA12 | |
| SCHEMBL29837229 | 0.75 | CYP1A2 (0.87) | CYP2A6CYP1A2TDP1CA9CA12 | |
| SCHEMBL6056946 | 0.75 | CYP1A2 (0.87) | CYP2A6CYP1A2TDP1CA9CA12 | |
| SCHEMBL4368477 | 0.75 | CYP1A2 (0.87) | CYP2A6CYP1A2TDP1CA9CA12 | |
| SCHEMBL2463834 | 0.75 | CYP1A2 (0.87) | CYP2A6CYP1A2TDP1CA9CA12 | |
| SCHEMBL2490023 | 0.75 | CYP1A2 (0.87) | CYP2A6CYP1A2TDP1CA9CA12 | |
| SCHEMBL31612403 | 0.75 | CYP1A2 (0.87) | CYP2A6CYP1A2TDP1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020215388-A1 | DEEP RED LIGHT THERMALLY ACTIVATED DELAYED FLUORESCENCE MATERIAL, PREPARATION METHOD THEREFOR, AND ELECTROLUMINESCENT DEVICE | 武汉华星光电半导体显示技术有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-8394512-B2 | Phosphaphenanthrene compounds and organic light emitting diode using the same | INKTEC CO., LTD. (KR) | 2013-03-12 | — | — | US | disclosed |
| US-20100252818-A1 | PHOSPHAPHENANTHRENE COMPOUNDS AND ORGANIC LIGHT EMITTING DIODE USING THE SAME | INKTEC CO., LTD. (KR) | 2010-10-07 | — | — | US | disclosed |
| US-7799776-B2 | Indoleamine 2,3-dioxygenase (IDO) inhibitors | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-09-21 | — | — | US | disclosed |
| US-7799776-B2 | Indoleamine 2,3-dioxygenase (IDO) inhibitors | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-09-21 | — | — | US | disclosed |
| EP-2134808-A1 | PHOSPHAPHENANTHRENE COMPOUNDS AND ORGANIC LIGHT EMITTING DIODE USING THE SAME | Inktec Co., Ltd. (KR) | 2009-12-23 | — | — | EP | disclosed |
| EP-2130826-A1 | Annulins A, B, C or analogs as indoleamine 2,3-dioxygenase (IDO) inhibitors for treatment of cancer | The University of British Columbia (CA) | 2009-12-09 | — | — | EP | disclosed |
| US-20090042868-A1 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitors | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20090042868-A1 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitors | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-02-12 | — | — | US | disclosed |
| WO-2008123722-A1 | PHOSPHAPHENANTHRENE COMPOUNDS AND ORGANIC LIGHT EMITTING DIODE USING THE SAME | INKTEC CO., LTD. (KR) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100252818-A1 | PHOSPHAPHENANTHRENE COMPOUNDS AND ORGANIC LIGHT EMITTING DIODE USING THE SAME | DDT, PPOX, ODC1 | CYP2A6 760/4885CYP1A2 419/4885TDP1 2028/4885 |
| US-20090042868-A1 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitors | IDO1, IDO2, TDO2 | CYP2A6 576/4885CYP1A2 363/4885TDP1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.